NCT07287917 2026-03-12
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Aminex Therapeutics, Inc.
Phase 1/2 Recruiting
Clinical Trials
14 trialsNCT02523014 2026-03-04
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT07294677 2026-03-04
CAVALRY
University of Chicago
Phase 1/2 Recruiting
NCT06982521 2026-03-03
ReDiscover-2
Relay Therapeutics, Inc.
Phase 3 Recruiting
NCT07281833 2026-02-27
CAPIcorn
West German Study Group
Phase 3 Recruiting
NCT07343960 2026-02-24
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
Phase 1 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT06635447 2026-01-13
CAPItrue
AstraZeneca
Phase 3 Recruiting
NCT05563220 2026-01-06
ELEVATE
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05039801 2025-10-14
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05593497 2025-04-16
SNARE
VA Office of Research and Development
Phase 2 Recruiting
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT06607757 2025-04-02
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
GBG Forschungs GmbH
Phase 2 Recruiting
NCT05720260 2024-06-10
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
National Taiwan University Hospital
Phase 2 Recruiting